A detailed history of Federated Hermes, Inc. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,209 shares of PLRX stock, worth $27,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,209
Holding current value
$27,214
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.52 - $14.35 $23,238 - $31,699
2,209 New
2,209 $24,000
Q3 2022

Nov 14, 2022

SELL
$7.67 - $24.23 $1.93 Million - $6.1 Million
-251,763 Reduced 75.95%
79,732 $1.67 Million
Q2 2022

Aug 15, 2022

BUY
$4.11 - $8.75 $272,587 - $580,326
66,323 Added 25.01%
331,495 $2.66 Million
Q1 2022

May 13, 2022

BUY
$7.01 - $14.1 $1.6 Million - $3.22 Million
228,554 Added 624.16%
265,172 $1.86 Million
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.26 $449,302 - $668,644
36,618 New
36,618 $494,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $600M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.